Insulinoma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}{{AE}}{{PSD}} | ||
==Overview== | ==Overview== | ||
Insulinoma must be differentiated from hypoglycemia due to sulfonylurea or insulin abuse | Insulinoma must be differentiated from autoimmune hypoglycemia, hypoglycemia due to sulfonylurea or insulin abuse, factitious hypoglycemia, noninsulinoma pancreatogenic hypoglycemia syndrome (NIPHS), familial persistent hyperinsulinemia, and nesidioblastosis. | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Insulinoma must be differentiated from: | Insulinoma must be differentiated from: |
Revision as of 19:49, 7 October 2015
Insulinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Insulinoma differential diagnosis On the Web |
American Roentgen Ray Society Images of Insulinoma differential diagnosis |
Risk calculators and risk factors for Insulinoma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Insulinoma must be differentiated from autoimmune hypoglycemia, hypoglycemia due to sulfonylurea or insulin abuse, factitious hypoglycemia, noninsulinoma pancreatogenic hypoglycemia syndrome (NIPHS), familial persistent hyperinsulinemia, and nesidioblastosis.
Differential Diagnosis
Insulinoma must be differentiated from:
- Hypoglycemia due to sulfonylurea or insulin abuse
- Autoimmune hypoglycemia
- Factitious hypoglycemia
- Noninsulinoma pancreatogenic hypoglycemia syndrome (NIPHS)
- Familial persistent hyperinsulinemia
- Nesidioblastosis
References